Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study. Fumery M, Caron B, Hebuterne X, Altwegg R, et al. Clin Gastroenterol Hepatol 2024 May 8:S1542-3565(24)00423.

Read + Share

Amedeo Smart

Independent Medical Education

Fumery M, Caron B, Hebuterne X, Altwegg R, et al. Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study. Clin Gastroenterol Hepatol 2024 May 8:S1542-3565(24)00423.
PMID: 38729389